High-Flow Nasal Cannula Therapy in Patients With COVID-19: Predictive Response Factors

Area of Science:

• Critical Care Medicine
• Pulmonology
• Infectious Diseases

Background:

• COVID-19 pneumonia frequently causes hypoxemic respiratory failure, increasing ICU admissions.
• Limited ICU beds and ventilation equipment necessitate alternative respiratory support strategies.
• High-flow nasal cannula (HFNC) offers an alternative to invasive ventilation for COVID-19 patients, but its efficacy and safety remain debated.

Purpose of the Study:

• To evaluate the performance of HFNC therapy in COVID-19 patients with hypoxemic respiratory failure.
• To identify predictors of favorable response to HFNC therapy.
• To assess the impact of HFNC on mortality and oxygenation.

Main Methods:

• A prospective observational study included 128 hospitalized adult COVID-19 patients requiring oxygen therapy.
• Clinical and laboratory parameters were collected to analyze HFNC therapy outcomes.
• Logistic regression and ROX index were used to predict therapy success or failure.

Main Results:

• The overall success rate of HFNC therapy was 53% in the studied cohort.
• Factors predicting therapy failure included high Charlson comorbidity score, oxygen flow requirement, and elevated breathing frequency.
• The ROX index demonstrated predictive value for HFNC success (AUC 0.7) and failure.

Conclusions:

• HFNC therapy in COVID-19 patients with respiratory distress is associated with reduced mortality and improved oxygenation.
• Close monitoring of patient parameters, particularly the ROX index, is crucial for patient selection and timely escalation to invasive ventilation.
• HFNC can be a valuable tool in managing COVID-19 respiratory failure, optimizing resource utilization during pandemics.